메티실린 내성 황색포도상구균(MRSA) : 인사이트, 역학 및 시장 예측(-2034년)

Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insight, Epidemiology, and Market Forecast - 2034

US $ 7,950 ￦ 10,908,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,925 ￦ 16,362,000

PDF (2-3 User License)

PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 15,900 ￦ 21,816,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 23,850 ￦ 32,724,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 주요 7개국 메티실린 내성 황색포도상구균(MRSA) 시장을 조사했으며, 질병 배경 및 개요, 역학, 치료 및 관리 개요, 시장 성장 촉진요인 및 장벽, 미충족 수요, 시판 중인 의약품 및 파이프라인 의약품 프로파일, 주요 국가별 시장 규모 추이 및 예측, 경쟁 구도, 시장 잠재력 등을 조사하여 최적의 기회를 발굴하고 시장의 잠재력을 평가합니다.

대상 지역

• 미국
• 유럽 5개국(독일, 프랑스, 이탈리아, 스페인, 영국)
• 일본

조사 기간 : 2020-2034년

보고서 하이라이트

• 메티실린 내성 황색포도상구균(MRSA) 시장은 질병에 대한 인식이 높아지고 전 세계적으로 의료비 지출이 증가함에 따라 향후 몇 년동안 변화를 보일 것으로 예상됩니다.
• 기업과 연구기관들은 메티실린 내성 황색포도상구균(MRSA) 연구개발에 영향을 미칠 수 있는 과제를 분석하고 기회를 모색하기 위해 노력하고 있습니다. 개발 중인 치료제는 질병을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞추었습니다.
• 대기업들이 메티실린 내성 황색포도상구균(MRSA) 치료제를 개발하기 위해 노력하고 있습니다. 새로운 치료제의 출시는 시장에 큰 영향을 미칠 것으로 예상됩니다.
• 메티실린 내성 황색포도상구균(MRSA)의 새로운 치료제를 개발하기 위해서는 질병 병태에 대한 더 깊은 이해가 필요합니다.
• 개발 단계별(Phase III 및 Phase II) 파이프라인 자산에 대한 상세한 분석, 다양한 신흥 동향, 상세한 임상 프로파일, 주요 교차 경쟁, 출시일, 제품 개발 활동을 포함한 파이프라인 의약품에 대한 비교 분석을 통해 R&D 활동의 전반적인 시나리오를 파악하여 치료 포트폴리오에 대한 의사결정 과정에서 고객사의 의사결정 과정을 지원합니다.

목차

제1장 주요 인사이트

제2장 메티실린 내성 황색포도상구균(MRSA) : 주요 요약

제3장 메티실린 내성 황색포도상구균(MRSA) : 경쟁 분석

제4장 메티실린 내성 황색포도상구균(MRSA) : 시장 개요

• 전체 시장 점유율(%) 분포 : 2020년
• 전체 시장 점유율(%) 분포 : 2034년

제5장 메티실린 내성 황색포도상구균(MRSA) : 질환의 배경과 개요

• 징후와 증상
• 병태생리
• 위험요인
• 진단

제6장 환자 여정

제7장 메티실린 내성 황색포도상구균(MRSA) : 역학 및 환자 인구

• 역학 : 주요 조사 결과
• 전제와 근거 : 주요 7개국
• 역학 시나리오 : 주요 7개국
  • 주요 7개국의 메티실린 내성 황색포도상구균(MRSA) 역학 시나리오 : 2020-2034년
• 역학 : 미국
• 역학 : 유럽 5개국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
• 역학 : 일본

제8장 치료 알고리즘, 현재의 치료제 및 의료 행위

• 메티실린 내성 황색포도상구균(MRSA) 치료와 관리
• 메티실린 내성 황색포도상구균(MRSA) 치료 알고리즘

제9장 미충족 요구

제10장 메티실린 내성 황색포도상구균(MRSA)의 치료 주요 엔드포인트

제11장 출시 제품

• 주요 7개국의 출시 제품 리스트
• 의약품명/기업명
  • 제품 설명
  • 규제 마일스톤
  • 기타 개발 활동
  • 중요 임상시험
  • 주요 임상시험 개요

제12장 신흥 치료제

• 주요 경쟁
• 의약품명/기업명
  • 제품 설명
  • 기타 개발 활동
  • 임상 개발
  • 안전성과 유효성
  • 제품 개요

제13장 메티실린 내성 황색포도상구균(MRSA) : 주요 7개국 시장 분석

• 주요 조사 결과
• 주요 7개국 시장 규모
• 주요 7개국 시장 규모 : 치료제별

제14장 속성 분석

제15장 주요 7개국 : 시장 전망

• 미국 : 시장 규모
• 유럽 5개국 : 시장 규모·전망
• 독일
• 프랑스
• 이탈리아
• 스페인
• 영국
• 일본 시장 전망

제16장 메티실린 내성 황색포도상구균(MRSA) : 접근 및 상환 개요

제17장 KOL(Key Opinion Leader)의 견해

제18장 시장 성장 촉진요인

제19장 시장 장벽

제20장 부록

제21장 DelveInsight의 능력

제22장 면책사항

제23장 DelveInsight에 대해

LSH

영문 목차

영문목차

DelveInsight's "Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Methicillin-resistant Staphylococcus aureus (MRSA), historical and forecasted epidemiology as well as the Methicillin-resistant Staphylococcus aureus (MRSA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Methicillin-resistant Staphylococcus aureus (MRSA) market report provides current treatment practices, emerging drugs, Methicillin-resistant Staphylococcus aureus (MRSA) market share of the individual therapies, current and forecasted Methicillin-resistant Staphylococcus aureus (MRSA) market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Methicillin-resistant Staphylococcus aureus (MRSA) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Methicillin-resistant Staphylococcus aureus (MRSA) Disease Understanding and Treatment Algorithm

The DelveInsight Methicillin-resistant Staphylococcus aureus (MRSA) market report gives a thorough understanding of the Methicillin-resistant Staphylococcus aureus (MRSA) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Methicillin-resistant Staphylococcus aureus (MRSA).

Treatment

It covers the details of conventional and current medical therapies available in the Methicillin-resistant Staphylococcus aureus (MRSA) market for the treatment of the condition. It also provides Methicillin-resistant Staphylococcus aureus (MRSA) treatment algorithms and guidelines in the United States, Europe, and Japan.

Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology

The Methicillin-resistant Staphylococcus aureus (MRSA) epidemiology division provide insights about historical and current Methicillin-resistant Staphylococcus aureus (MRSA) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Methicillin-resistant Staphylococcus aureus (MRSA) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology

The epidemiology segment also provides the Methicillin-resistant Staphylococcus aureus (MRSA) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Methicillin-resistant Staphylococcus aureus (MRSA) Drug Chapters

Drug chapter segment of the Methicillin-resistant Staphylococcus aureus (MRSA) report encloses the detailed analysis of Methicillin-resistant Staphylococcus aureus (MRSA) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Methicillin-resistant Staphylococcus aureus (MRSA) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Methicillin-resistant Staphylococcus aureus (MRSA) treatment.

Methicillin-resistant Staphylococcus aureus (MRSA) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Methicillin-resistant Staphylococcus aureus (MRSA) treatment.

Methicillin-resistant Staphylococcus aureus (MRSA) Market Outlook

The Methicillin-resistant Staphylococcus aureus (MRSA) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Methicillin-resistant Staphylococcus aureus (MRSA) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Methicillin-resistant Staphylococcus aureus (MRSA) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Methicillin-resistant Staphylococcus aureus (MRSA) market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Methicillin-resistant Staphylococcus aureus (MRSA) market in 7MM.

The United States Market Outlook

This section provides the total Methicillin-resistant Staphylococcus aureus (MRSA) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Methicillin-resistant Staphylococcus aureus (MRSA) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Methicillin-resistant Staphylococcus aureus (MRSA) market size and market size by therapies in Japan is also mentioned.

Methicillin-resistant Staphylococcus aureus (MRSA) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Methicillin-resistant Staphylococcus aureus (MRSA) market or expected to get launched in the market during the study period 2020-2034. The analysis covers Methicillin-resistant Staphylococcus aureus (MRSA) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Methicillin-resistant Staphylococcus aureus (MRSA) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Methicillin-resistant Staphylococcus aureus (MRSA) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Methicillin-resistant Staphylococcus aureus (MRSA) emerging therapies.

Reimbursement Scenario in Methicillin-resistant Staphylococcus aureus (MRSA)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Methicillin-resistant Staphylococcus aureus (MRSA) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Methicillin-resistant Staphylococcus aureus (MRSA) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Methicillin-resistant Staphylococcus aureus (MRSA) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Methicillin-resistant Staphylococcus aureus (MRSA), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Methicillin-resistant Staphylococcus aureus (MRSA) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Methicillin-resistant Staphylococcus aureus (MRSA) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Methicillin-resistant Staphylococcus aureus (MRSA) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Methicillin-resistant Staphylococcus aureus (MRSA) market

Report Highlights:

• In the coming years, Methicillin-resistant Staphylococcus aureus (MRSA) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Methicillin-resistant Staphylococcus aureus (MRSA) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Methicillin-resistant Staphylococcus aureus (MRSA). Launch of emerging therapies will significantly impact the Methicillin-resistant Staphylococcus aureus (MRSA) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Methicillin-resistant Staphylococcus aureus (MRSA)
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Methicillin-resistant Staphylococcus aureus (MRSA) Report Insights

• Patient Population
• Therapeutic Approaches
• Methicillin-resistant Staphylococcus aureus (MRSA) Pipeline Analysis
• Methicillin-resistant Staphylococcus aureus (MRSA) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Methicillin-resistant Staphylococcus aureus (MRSA) Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Methicillin-resistant Staphylococcus aureus (MRSA) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Methicillin-resistant Staphylococcus aureus (MRSA) market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Methicillin-resistant Staphylococcus aureus (MRSA) total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Methicillin-resistant Staphylococcus aureus (MRSA) market size during the forecast period (2024-2034)?
• At what CAGR, the Methicillin-resistant Staphylococcus aureus (MRSA) market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Methicillin-resistant Staphylococcus aureus (MRSA) market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Methicillin-resistant Staphylococcus aureus (MRSA) market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Methicillin-resistant Staphylococcus aureus (MRSA)?
• What is the historical Methicillin-resistant Staphylococcus aureus (MRSA) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Methicillin-resistant Staphylococcus aureus (MRSA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Methicillin-resistant Staphylococcus aureus (MRSA)?
• Out of all 7MM countries, which country would have the highest prevalent population of Methicillin-resistant Staphylococcus aureus (MRSA) during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Methicillin-resistant Staphylococcus aureus (MRSA) treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Methicillin-resistant Staphylococcus aureus (MRSA) in the USA, Europe, and Japan?
• What are the Methicillin-resistant Staphylococcus aureus (MRSA) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Methicillin-resistant Staphylococcus aureus (MRSA)?
• How many therapies are developed by each company for Methicillin-resistant Staphylococcus aureus (MRSA) treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Methicillin-resistant Staphylococcus aureus (MRSA) treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Methicillin-resistant Staphylococcus aureus (MRSA) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Methicillin-resistant Staphylococcus aureus (MRSA) and their status?
• What are the key designations that have been granted for the emerging therapies for Methicillin-resistant Staphylococcus aureus (MRSA)?
• What are the global historical and forecasted market of Methicillin-resistant Staphylococcus aureus (MRSA)?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Methicillin-resistant Staphylococcus aureus (MRSA) market
• To understand the future market competition in the Methicillin-resistant Staphylococcus aureus (MRSA) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Methicillin-resistant Staphylococcus aureus (MRSA) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Methicillin-resistant Staphylococcus aureus (MRSA) market
• To understand the future market competition in the Methicillin-resistant Staphylococcus aureus (MRSA) market

Table of Contents

1. Key Insights

2. Executive Summary of Methicillin-resistant Staphylococcus aureus (MRSA)

3. Competitive Intelligence Analysis for Methicillin-resistant Staphylococcus aureus (MRSA)

4. Methicillin-resistant Staphylococcus aureus (MRSA): Market Overview at a Glance

• 4.1. Methicillin-resistant Staphylococcus aureus (MRSA) Total Market Share (%) Distribution in 2020
• 4.2. Methicillin-resistant Staphylococcus aureus (MRSA) Total Market Share (%) Distribution in 2034

5. Methicillin-resistant Staphylococcus aureus (MRSA): Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Methicillin-resistant Staphylococcus aureus (MRSA) Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Methicillin-resistant Staphylococcus aureus (MRSA) Treatment and Management
• 8.2. Methicillin-resistant Staphylococcus aureus (MRSA) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Methicillin-resistant Staphylococcus aureus (MRSA) Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Methicillin-resistant Staphylococcus aureus (MRSA): Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Methicillin-resistant Staphylococcus aureus (MRSA) Market Size in 7MM
• 13.3. Methicillin-resistant Staphylococcus aureus (MRSA) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Methicillin-resistant Staphylococcus aureus (MRSA) Total Market Size in the United States
  • 15.1.2. Methicillin-resistant Staphylococcus aureus (MRSA) Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Methicillin-resistant Staphylococcus aureus (MRSA) Total Market Size in Germany
  • 15.3.2. Methicillin-resistant Staphylococcus aureus (MRSA) Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Methicillin-resistant Staphylococcus aureus (MRSA) Total Market Size in France
  • 15.4.2. Methicillin-resistant Staphylococcus aureus (MRSA) Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Methicillin-resistant Staphylococcus aureus (MRSA) Total Market Size in Italy
  • 15.5.2. Methicillin-resistant Staphylococcus aureus (MRSA) Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Methicillin-resistant Staphylococcus aureus (MRSA) Total Market Size in Spain
  • 15.6.2. Methicillin-resistant Staphylococcus aureus (MRSA) Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Methicillin-resistant Staphylococcus aureus (MRSA) Total Market Size in the United Kingdom
  • 15.7.2. Methicillin-resistant Staphylococcus aureus (MRSA) Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Methicillin-resistant Staphylococcus aureus (MRSA) Total Market Size in Japan
  • 15.8.3. Methicillin-resistant Staphylococcus aureus (MRSA) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Methicillin-resistant Staphylococcus aureus (MRSA)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

관련자료